Kim Sun Bean, Ryoo Seungeun, Huh Kyungmin, Joo Eun Jeong, Kim Youn Jeong, Choi Won Suk, Kim Yae Jean, Yoon Young Kyung, Heo Jung Yeon, Seo Yu Bin, Jeong Su Jin, Park Dong Ah, Yu Su Yeon, Lee Hyeon Jeong, Kim Jimin, Jin Yan, Park Jungeun, Peck Kyong Ran, Choi Miyoung, Yeom Joon Sup
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.
Infect Chemother. 2021 Mar;53(1):166-219. doi: 10.3947/ic.2021.0303.
Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
尽管全球都在努力减缓新冠病毒的传播,但2019冠状病毒病(COVID-19)已演变成一场大流行病,夺走了超过200万人的生命。目前有许多正在进行的临床研究旨在寻找治疗方案,而且每天都有许多研究成果发表。尽管疗效各不相同,但已经发现了一些有效的治疗方案。因此,有必要制定一种基于证据的方法,持续检查新证据,并据此更新建议。在此,我们根据最新证据提供关于COVID-19药物治疗的指南。